Guangdong Zhongsheng Pharmaceutical Valuation
Is 002317 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 002317 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 002317 (CN¥13.04) is trading above our estimate of fair value (CN¥5.21)
Significantly Below Fair Value: 002317 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 002317?
Key metric: As 002317 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 002317's PE Ratio? | |
|---|---|
| PE Ratio | 83.2x |
| Earnings | CN¥132.58m |
| Market Cap | CN¥11.03b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.9x |
| Enterprise Value/EBITDA | 28.4x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does 002317's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.9x | ||
600572 Zhejiang CONBA PharmaceuticalLtd | 23.6x | 24.8% | CN¥11.5b |
600993 Mayinglong Pharmaceutical Group | 22.4x | 18.9% | CN¥10.8b |
600422 KPC PharmaceuticalsInc | 24.5x | 28.1% | CN¥10.9b |
300357 Zhejiang Wolwo Bio-Pharmaceutical | 37.2x | 23.3% | CN¥11.6b |
002317 Guangdong Zhongsheng Pharmaceutical | 83.2x | 41.7% | CN¥11.0b |
Price-To-Earnings vs Peers: 002317 is expensive based on its Price-To-Earnings Ratio (83.2x) compared to the peer average (26.9x).
Price to Earnings Ratio vs Industry
How does 002317's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 002317 is expensive based on its Price-To-Earnings Ratio (83.2x) compared to the CN Pharmaceuticals industry average (31.1x).
Price to Earnings Ratio vs Fair Ratio
What is 002317's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 83.2x |
| Fair PE Ratio | 37.4x |
Price-To-Earnings vs Fair Ratio: 002317 is expensive based on its Price-To-Earnings Ratio (83.2x) compared to the estimated Fair Price-To-Earnings Ratio (37.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.80
7D
-3.9%
1Y
12.1%
Jiangsu Kanion PharmaceuticalLtd
CN¥8.1b
Researches and develops, produces, and sells Chinese medicines.
600557
CN¥14.29
7D
-4.2%
1Y
-23.6%
Dong-E-E-JiaoLtd
CN¥36.4b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥56.60
7D
-3.0%
1Y
13.2%